Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic priapism
- PMID: 29278308
- PMCID: PMC5824375
- DOI: 10.1111/jcmm.13411
Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic priapism
Abstract
Penile fibrosis caused by ischemic priapism (IP) adversely affects patients' erectile function. We explored the role of lysyl oxidase (LOX) in rat and human penes after ischemic priapism (IP) to verify the effects of anti-LOX in relieving penile fibrosis and preventing erectile dysfunction caused by IP in rats. Seventy-two rats were randomly divided into six groups: control group, control + β-aminopropionitrile (BAPN) group, 9 hrs group, 9 hrs + BAPN group, 24 hrs group, and 24 hrs + BAPN group. β-aminopropionitrile (BAPN), a specific inhibitor of LOX, was administered in the drinking water. At 1 week and 4 weeks, half of the rats in each group were randomly selected for the experiment. Compared to the control group, the erectile function of IP rats was significantly decreased while the expression of LOX in the corpus cavernosum was significantly up-regulated in both 9 and 24 hrs group. Proliferated fibroblasts, decreased corpus cavernosum smooth muscle cells/collagen ratios, destroyed endothelial continuity, deposited abnormal collagen and disorganized fibers were observed in IP rats. The relative content of collage I and III was not obviously different among the groups. β-aminopropionitrile (BAPN) could effectively improve the structure and erectile function of the penis, and enhance recovery. The data in this study suggests that LOX may play an important role in the fibrosis of corpus cavernosum after IP and anti-LOX may be a novel target for patients suffering with IP.
Keywords: erectile dysfunction; fibrosis; ischaemic priapism; lysyl oxidase.
© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Figures
References
-
- Muneer A, Ralph D. Guideline of guidelines: priapism. BJU Int. 2017; 119: 204–8. - PubMed
-
- Salonia A, Eardley I, Giuliano F, et al European Association of Urology guidelines on priapism. Eur Urol. 2014; 65: 480–9. - PubMed
-
- Yuan J, Desouza R, Westney OL, et al Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl. 2008; 10: 88–101. - PubMed
-
- Pryor J, Akkus E, Alter G, et al Priapism. J Sex Med. 2004; 1: 116–20. - PubMed
-
- Mercier N, Kakou A, Challande P, et al Comparison of the effects of semicarbazide and beta‐aminopropionitrile on the arterial extracellular matrix in the Brown Norway rat. Toxicol Appl Pharmacol. 2009; 239: 258–67. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
